SynthesisAntimicrobial resistance and infection control2023
Epidemiology of multidrug-resistant Klebsiella pneumoniae infection in clinical setting in South-Eastern Asia: a systematic review and meta-analysis.
Synthesis in Antimicrobial resistance and infection control, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in sub-Saharan Africa: a systematic review and meta-analysis from a One Health perspective.BMC infectious diseases · 2025Pooled it
- Systematic review of multidrug-resistantFrontiers in microbiology · 2025Pooled it
- Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects.Antimicrobial agents and chemotherapy · 2025Trial
- Therapeutic strategies against biofilm-associated multidrug-resistantFrontiers in microbiology · 2026Review
- Adjuvant-driven epitope hierarchy correlates with the protective efficacy of FimA vaccine againstFrontiers in immunology · 2026Article
- Novel bacteriophages effectively target multidrug-resistant clinical isolates of Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study.Antibiotics (Basel, Switzerland) · 2025Article
- The Burden of Hospitalization Due toHealth science reports · 2025Review
- Epidemiology, resistance profiles, and risk factors of multidrug-resistant Klebsiella pneumoniae: experience from a low- and middle-income country.BMC infectious diseases · 2025Article
- Multidrug-resistantmSystems · 2025Article
- Predisposing Factors Associated with Third-Generation Cephalosporin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Prevalence of colistin resistance in multidrug-resistantJAC-antimicrobial resistance · 2025Review
- Low prevalence but high resistance of Extended Spectrum Beta-lactamase producingAfrican health sciences · 2025Article
- Probiotic cell-free supernatant as effective antimicrobials against Klebsiella pneumoniae and reduce antibiotic resistance development.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Article
- Bioinformatics analysis of the in silico engineered protein vaccine with and without Escherichia coli heat labile enterotoxin adjuvant on the model of Klebsiella pneumoniae.Scientific reports · 2025Article
- Major Predominant Serotypes and Virulence Genes and Antibiotic Resistance Characteristics ofInfection and drug resistance · 2025Article
- High Prevalence of Multidrug-resistantMateria socio-medica · 2025Article
- Clinical Outcomes and Mortality Predictors of Klebsiella Pneumoniae Pneumonia in Vietnamese Elderly: a Prospective Cohort Study.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising prevalence of multidrug-resistant (MDR) and extended-spectrum beta lactamase-resistant (ESBL) Klebsiella pneumoniae (K. pneumoniae) is an important global public health challenge. This threat is even more pertinent in clinical settings. Morbidity and mortality associated with this condition are alarming particularly in the developing regions of the world. A comprehensive evaluation of the epidemiology of this phenomenon will assist towards the global effort of reducing its burden. So, this systematic review and meta-analysis was conducted to evaluate the epidemiology of MDR K. pneumoniae in South-Eastern Asia (SEA). The study was done under the PRISMA guidelines and was preceded by the development of a priori protocol. The protocol was then registered in PROSPERO-the public registry for systematic reviews. Seven important outcomes which include the assessment of the overall MDR K. pneumoniae prevalence were designed to be evaluated. A literature search was carried out in five selected electronic databases and 4389 were screened. Of these articles, 21 studies that met the eligibility criteria were included in the review. Relevant data were extracted from the included studies. By conducting a quality effect meta-analysis, the pooled prevalence for MDR and ESBL K. pneumoniae in SEA was estimated at 55% (CI 9-96) and 27% (CI 32-100) respectively. The review also identified ESBL genes types of allodemic situations occurring mostly in respiratory tract infections. The high prevalence of MDR and ESBL K. pneumoniae in this subregion is highly significant and of both public health and clinical relevance. Overall, the findings of this review will assist in the effective prevention and control of this threat in SEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.